Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC (IMPACT31)
IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Joann Peters, MHA
- 전화번호: 434-825-2551
- 이메일: peters@geneostx.com
연구 장소
-
-
-
Auckland, 뉴질랜드, 1023
- 모병
- Auckland City Hospital (Te Toka Tumai)
-
연락하다:
- Principal Investigator, MD
- 전화번호: 22932 64 0800 488 434
- 이메일: LiverResearchUnit@adhb.govt.nz
-
-
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 아직 모집하지 않음
- Emory University
-
연락하다:
- Principal Investigator, MD
- 전화번호: 404-251-1278
- 이메일: kathleen.marie.coleman@emory.edu
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- 모병
- Louisiana State University Health Sciences Center
-
연락하다:
- Principal Investigator, MD
- 전화번호: 504-568-4750
- 이메일: omoave@lsuhsc.edu
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University
-
연락하다:
- Principal Investigator, MD
- 전화번호: 410-955-8893
- 이메일: GIClinicalTrials@jh.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 아직 모집하지 않음
- University of Michigan
-
연락하다:
- Principal Investigator, MD
- 전화번호: 734-936-8643
- 이메일: ndparikh@med.umich.edu
-
-
New York
-
New York, New York, 미국, 10029
- 모병
- Icahn School of Medicine at Mount Sinai
-
연락하다:
- Principal Investigator, MD
- 전화번호: 212-241-7840
- 이메일: denise.rodriguez3@mssm.edu
-
New York, New York, 미국, 10027
- 아직 모집하지 않음
- New York Presbyterian Hospital-Columbia University Irving Medical Center
-
연락하다:
- Principal Investigator, MD
- 전화번호: 212-342-5162
- 이메일: Cancerclinicaltrials@cumc.columbia.edu
-
-
Texas
-
Houston, Texas, 미국, 77030
- 아직 모집하지 않음
- MD Anderson Cancer Center
-
연락하다:
- Principal Investigator, MD
- 전화번호: 713-792-2828
- 이메일: GIClinicalTrials@mdanderson.org
-
-
Washington
-
Seattle, Washington, 미국, 98109
- 아직 모집하지 않음
- Fred Hutchinson Cancer Center
-
연락하다:
- Principal Investigator, MD
- 전화번호: 206-667-1392
- 이메일: giresearch@fredhutch.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Written informed consent
- ≥18 years of age
- Histologically or cytologically confirmed diagnosis of HCC (not accepted: fibrolamellar, sarcomatoid, mixed cholangiocarcinoma)
- Child-Pugh Class A liver score
- Documented virology status of hepatitis
- Availability of a representative post-resection tumor tissue sample
- ECOG performance status of 0 or 1
- Adequate organ function
- Women of childbearing potential (WOCBP) and men must be willing to use an adequate method of contraception
Exclusion Criteria:
- Is currently participating in and receiving study drug or has participated in a study of an investigational agent and received study drug or used an investigation device, within 4 weeks to baseline
- Evidence of residual, recurrent, or metastatic disease at randomization
- Active or history of autoimmune disease or immune deficiency
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- Diagnosed additional malignancy within 5 years prior to baseline, except for: (a) non-invasive carcinomas subject to successful curative treatment in the opinion of the investigator which require no further therapy and (b) other malignancies for which subjects have undergone potentially curative therapy and have been considered disease free for at least 3 years prior to screening.
- Active infection requiring systemic therapy
- Is pregnant, breastfeeding or expecting to conceive or father children within the study's projected duration
- History of human immunodeficiency virus (HIV) (HIV I/II antibodies).
- Co-infection with HBV and hepatitis D viral infection
- Co-infection with HBV and HCV
- Has received a live vaccine within 30 days of planned start of study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Personalized Immunotherapy for Cancer:
GNOS-PV02 + INO-9012 ID followed by electroporation every 3 weeks for 4 doses, then every 9 weeks (Q9W) until week 104, then every 12 weeks (Q12W) until week 260 followed by 3 years follow-up survival |
delivered by intradermal injection and electroporation GNOS-PV02 + INO-9012 ID followed by electroporation cytokine interleukin-12 (IL-12), a vaccine adjuvant |
|
간섭 없음: Standard of Care
Active Surveillance for 5 years or until recurrence, plus 3 years follow-up survival. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recurrence-free survival
기간: Up to 5 years
|
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary HCC, as assessed by the investigator, or death due to any cause, whichever occurs first. |
Up to 5 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of treatment emergent adverse events (safety and tolerability)
기간: Up to 5 years
|
Summary adverse events according to CTCAE 6.0 |
Up to 5 years
|
|
Time to extra-hepatic spread or macro-vascular invasion
기간: Up to 5 years
|
Time to extra-hepatic spread or macro-vascular invasion (TTEHS/MVI) |
Up to 5 years
|
|
Overall survival
기간: Up to 5 years on study + 3 years follow up
|
OS is defined as time from randomization to death of any cause |
Up to 5 years on study + 3 years follow up
|
|
RFS rate at 12, 18 and 24 months as assessed by the investigator
기간: Randomization up to 12 months, 18 and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 and 24 months
|
|
RFS rate at 12, 18 and 24 months as assessed by the BIRC
기간: Randomization up to 12 months, 18 months and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 months and 24 months
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GT-31
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
At the time of registration, the sponsor has not yet determined whether de-identified individual participant data collected during the study will be shared. A decision regarding data sharing will be made following study completion and in accordance with sponsor policies, applicable regulations, and ethical considerations.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .